search
Back to results

The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors (RESIST)

Primary Purpose

Glioblastoma Multiforme of Brain, Brain Cancer

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Circuit-based resistance exercise (CRT)
Sponsored by
Nova Scotia Health Authority
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Glioblastoma Multiforme of Brain focused on measuring Exercise, Circuit-based resistance training, Intervention, Myopathy, Functional status, Quality of life, Randomized controlled trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • histologically confirmed diagnosis of either primary or secondary GBM
  • received any dose of DEX
  • Karnofsky Performance Status (KPS) >70
  • English fluency
  • physician approval
  • willingness to travel to Halifax to participate.

Exclusion Criteria:

  • unstable or symptomatic cardiac or pulmonary disease, injury or co-morbid disease that precludes ability to safely exercise
  • significant cognitive limitations
  • uncontrolled seizures associated with impaired awareness

Sites / Locations

  • QEII Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exercise Intervention

Wait-list Control

Arm Description

12-week circuit-based resistance exercise

Standard of care wait-list control group

Outcomes

Primary Outcome Measures

Functional Performance
Short Physical Performance Battery to assess activities of daily living
Grip strength
Measured by handheld dynamometer

Secondary Outcome Measures

Body Mass Index (BMI)
Weight (kg) and height (m) will be used to calculate BMI
Body composition and Muscle Mass
Arm, waist, and calf circumference (cm)
Muscle Mass
Muscle mass and quality - 3T diagnostic magnetic resonance imaging
Aerobic fitness
6 minute walk will be used to calculate aerobic fitness
Physical activity
Godin Leisure Time Physical Activity Questionnaire - Leisure Score Index will be used to calculate self-reported leisure physical activity
Physical, functional, emotional, and social/family quality of Life
Functional Assessment of Cancer Therapy - Brain (FACT-Br) - 50 item scale; total scale score range 0-200; higher scores indicate higher overall QOL
Fatigue
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) - 13 item scale; score range 0-52; higher scores indicate less fatigue
Cognitive functioning 1
Trail making test-b; Time taken to complete each task and number of errors made during each task are recorded and compared with normative data. Time to complete the task is recorded in seconds; the greater the number of seconds to complete the task, the greater the impairment.
Cognitive functioning 2
Hopkins Verbal Learning Test-Revised for memory; total recall and recognition scores will be calculated
General Health (EuroQol) 5 Dimension - 5 Level
Mobility, self-care, usual activities, pain/discomfort, anxiety/depression (EuroQol-5Dimension-5Level; EQ-5D-5L) - 5 dimensions; higher scores indicate higher problems
General Health (EuroQol) Visual Analog Scale
EuroQol Visual Analog Scale 0-100; lower scores indicate worse health

Full Information

First Posted
October 19, 2021
Last Updated
May 2, 2023
Sponsor
Nova Scotia Health Authority
Collaborators
Canadian Cancer Society (CCS)
search

1. Study Identification

Unique Protocol Identification Number
NCT05116137
Brief Title
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors
Acronym
RESIST
Official Title
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors (RESIST)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
March 1, 2022 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nova Scotia Health Authority
Collaborators
Canadian Cancer Society (CCS)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Glioblastoma patients are confronted with a debilitating disease associated with a low survival rate and poor quality of life. The goal of this study will be to reach a largely underrepresented population in the exercise literature and explore the role of a tailored circuit-based resistance training program on functional fitness (i.e., ability to carry out tasks of daily living) and associated health outcomes (e.g., quality of life) for GBM patients on active treatment.
Detailed Description
PROBLEM: Glioblastoma multiforme (GBM) is the most common brain malignancy accounting for approximately 48% of all brain tumors. GBMs are highly vascular and can cause vasogenic brain edema and mass effect, which can worsen the neurologic symptoms associated with the disease. Corticosteroids (i.e., Dexamethasone; DEX) are the treatment of choice to reduce vasogenic edema and intercranial pressure associated with GBM. However, the use of steroids comes at a cost. High dose steroid therapy and/or long-term use results in muscle myopathy (i.e., muscle weakness) in 10-60% of GBM patients, significantly reducing functional ability as well as quality of life (QOL). Thus, adjuvant therapies are needed to help patients maintain their functional ability and QOL. There is a wealth of evidence to support the use of exercise as an adjuvant therapy to improve functional ability as well as help manage treatment-related symptoms. Resistance training (RT) has been shown to increase muscle mass, strength, and functional ability in aging adults and several cancer populations. While limited, studies in GBM have shown that exercise is safe and feasible for this population and that it can improve functional performance. However, no specific research has been performed to determine whether RT can be successfully used in GBM to prevent or reduce steroid induced muscle myopathy. Therefore, the primary purpose of this study is to establish whether an individualized circuit-based RT program will improve functional fitness for patients on active treatment and receiving steroids. METHODS: This is a two-armed randomized control trial with repeated measures. Thirty-eight adult (18+ years) patients diagnosed with either primary or secondary GBM who are scheduled to receive standard radiation and concurrent adjuvant Temozolomide chemotherapy post-surgical debulking as well as received any dose of DEX will be recruited through the neuro-oncology clinic and the QEII Cancer Center. Patients will be randomly allocated to a standard of care group (SOC) or SOC+RT group (EX). Those in the SOC group will be advised to maintain an active lifestyle for the 12-week intervention whereas those in the EX group will receive a personalized 12-week circuit-based RT program. This program will consist of 3-4 supervised RT sessions/wk. During each session participants will perform a RT program that is comprised of 3 circuits. Each circuit will include 3 sets of 3 different exercises. Each exercise set will be 1 minute in duration (20 seconds/exercise) with 1 minute of rest between sets. Initial exercise intensity will be light and will increase throughout the program based on the participant's progress. All exercise programs will be designed and supervised by a Clinical Exercise Physiologist (CEP). The primary outcome measure for the study is functional performance which will be assessed using the Short Physical Performance Battery and hand grip strength. Secondary outcome measures will include body composition, aerobic fitness, physical activity levels, general health, QOL, fatigue, and cognitive function. All measures will be assessed pre/post-intervention. Safety and exercise adherence will be assessed throughout the study. ANALYSIS: Descriptive statistics will be used to describe the population, accrual, program adherence and safety. Outcome data will be analyzed using an intention to treat approach. All participants will be entered into a mixed effects model with participant group assignment (EX, SOC) at randomization and timepoint (pre- and post-test) as fixed factors and participant entered as a random factor. Due to feasibility in recruiting participants in the allotted time, the study will not be fully powered to detect sex-based differences; however, effect sizes associated with the intervention will be calculated and presented separately for each sex. SIGNIFICANCE: This study will demonstrate the not only is RT safe and feasible for those with GBM, but that it also significantly improves functional status by protecting against myopathy. This will help GBM patients maintain their independence which could lead to marked improvements in QOL.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioblastoma Multiforme of Brain, Brain Cancer
Keywords
Exercise, Circuit-based resistance training, Intervention, Myopathy, Functional status, Quality of life, Randomized controlled trial

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
RCTwith 1:1 allocation to intervention or wait-list control
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exercise Intervention
Arm Type
Experimental
Arm Description
12-week circuit-based resistance exercise
Arm Title
Wait-list Control
Arm Type
No Intervention
Arm Description
Standard of care wait-list control group
Intervention Type
Behavioral
Intervention Name(s)
Circuit-based resistance exercise (CRT)
Intervention Description
CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
Primary Outcome Measure Information:
Title
Functional Performance
Description
Short Physical Performance Battery to assess activities of daily living
Time Frame
Baseline to post-intervention (12-week) change
Title
Grip strength
Description
Measured by handheld dynamometer
Time Frame
Baseline to post-intervention (12-week) change
Secondary Outcome Measure Information:
Title
Body Mass Index (BMI)
Description
Weight (kg) and height (m) will be used to calculate BMI
Time Frame
Baseline to post-intervention (12-week) change
Title
Body composition and Muscle Mass
Description
Arm, waist, and calf circumference (cm)
Time Frame
Baseline to post-intervention (12-week) change
Title
Muscle Mass
Description
Muscle mass and quality - 3T diagnostic magnetic resonance imaging
Time Frame
Baseline to post-intervention (12-week) change
Title
Aerobic fitness
Description
6 minute walk will be used to calculate aerobic fitness
Time Frame
Baseline to post-intervention (12-week) change
Title
Physical activity
Description
Godin Leisure Time Physical Activity Questionnaire - Leisure Score Index will be used to calculate self-reported leisure physical activity
Time Frame
Baseline to post-intervention (12-week) change
Title
Physical, functional, emotional, and social/family quality of Life
Description
Functional Assessment of Cancer Therapy - Brain (FACT-Br) - 50 item scale; total scale score range 0-200; higher scores indicate higher overall QOL
Time Frame
Baseline to post-intervention (12-week) change
Title
Fatigue
Description
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) - 13 item scale; score range 0-52; higher scores indicate less fatigue
Time Frame
Baseline to post-intervention (12-week) change
Title
Cognitive functioning 1
Description
Trail making test-b; Time taken to complete each task and number of errors made during each task are recorded and compared with normative data. Time to complete the task is recorded in seconds; the greater the number of seconds to complete the task, the greater the impairment.
Time Frame
Baseline to post-intervention (12-week) change
Title
Cognitive functioning 2
Description
Hopkins Verbal Learning Test-Revised for memory; total recall and recognition scores will be calculated
Time Frame
Baseline to post-intervention (12-week) change
Title
General Health (EuroQol) 5 Dimension - 5 Level
Description
Mobility, self-care, usual activities, pain/discomfort, anxiety/depression (EuroQol-5Dimension-5Level; EQ-5D-5L) - 5 dimensions; higher scores indicate higher problems
Time Frame
Baseline to post-intervention (12-week) change
Title
General Health (EuroQol) Visual Analog Scale
Description
EuroQol Visual Analog Scale 0-100; lower scores indicate worse health
Time Frame
Baseline to post-intervention (12-week) change
Other Pre-specified Outcome Measures:
Title
Study Feasibility - Participant Accrual
Description
Participant accrual calculated as % of patients referred divided by number of patients consented to participation
Time Frame
Captured over the 12-week study period
Title
Study Feasibility - Participant Attrition
Description
Participant attrition calculated as % of patients who complete 12-week study divided by number who withdraw from study
Time Frame
Captured over the 12-week study period
Title
Study Feasibility - Participant Adherence
Description
Participant program adherence calculated as % of exercise sessions completed divided by total number of available exercise sessions over 12-week intervention
Time Frame
Captured over the 12-week study period
Title
Study safety
Description
Adverse events will be recorded
Time Frame
Captured over the 12-week study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: histologically confirmed diagnosis of either primary or secondary GBM received any dose of DEX Karnofsky Performance Status (KPS) >70 English fluency physician approval willingness to travel to Halifax to participate. Exclusion Criteria: unstable or symptomatic cardiac or pulmonary disease, injury or co-morbid disease that precludes ability to safely exercise significant cognitive limitations uncontrolled seizures associated with impaired awareness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott Grandy, PhD
Organizational Affiliation
Dahousie University and Nova Scotia Health Authority
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mary MacNeil, MD
Organizational Affiliation
Nova Scotia Health Authority
Official's Role
Principal Investigator
Facility Information:
Facility Name
QEII Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35507403
Citation
Keats MR, Grandy SA, Blanchard C, Fowles JR, Neyedli HF, Weeks AC, MacNeil MV. The Impact of Resistance Exercise on Muscle Mass in Glioblastoma in Survivors (RESIST): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2022 May 4;11(5):e37709. doi: 10.2196/37709.
Results Reference
derived

Learn more about this trial

The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors

We'll reach out to this number within 24 hrs